TB-500 / Thymosin Beta-4 is a synthetic peptide based on thymosin beta-4, a naturally occurring protein involved in cellular processes associated with tissue response and recovery. It is commonly explored in provider-directed recovery and regenerative wellness programs and should be evaluated based on the individual patient, treatment objective, and applicable prescribing information.
What It Is Used For
TB-500 / Thymosin Beta-4 is commonly considered in provider-directed programs focused on the following areas of interest:
Recovery Support — Often considered in provider-directed programs designed to support recovery following strenuous physical activity, training, or musculoskeletal stress.
Tissue Repair and Regenerative Wellness — May be explored within programs focused on tissue response and regenerative wellness objectives.
Musculoskeletal Support — May be considered for patients whose goals include musculoskeletal wellness and mobility-related recovery.
TB-500 / Thymosin Beta-4 should be evaluated against applicable prescribing information. Information provided by ALML is intended for healthcare professionals and does not replace independent clinical judgment.
How It Works
TB-500 / Thymosin Beta-4 is a synthetic peptide based on thymosin beta-4, a naturally occurring protein that participates in cellular processes associated with tissue response. Areas of biological activity include:
Areas being studied include:
Cell Migration and Tissue Organization — Thymosin beta-4 has been studied for its association with cellular processes involved in cell migration and tissue organization, areas of interest in recovery and regenerative research.
Actin Binding and Cytoskeletal Dynamics — Thymosin beta-4 is known to bind actin, a relationship that has been investigated for its role in cytoskeletal dynamics and cellular movement.
Recovery and Regenerative Pathways — Preclinical research has explored potential effects on cellular processes associated with tissue repair and recovery following mechanical stress.
Inflammatory Signaling — Preclinical studies have investigated potential effects on biological pathways involved in inflammatory responses.
Clinical use of TB-500 / Thymosin Beta-4 varies by patient-specific factors and applicable prescribing information. The treating healthcare professional remains responsible for all clinical decision-making. This information is educational and does not establish clinical efficacy for any specific use.
Clinical Information
Healthcare professionals should independently evaluate the available evidence, patient-specific factors, potential risks, and applicable regulatory requirements before considering TB-500 / Thymosin Beta-4 for a patient.
Include these considerations:
Patient-Specific Assessment Required — Providers should consider the patient's medical history, current medications, allergies, pregnancy or breastfeeding status, and other relevant clinical factors before use.
Use Within Approved and Appropriate Context — TB-500 / Thymosin Beta-4 should be evaluated against applicable prescribing information and used only where clinically appropriate for the individual patient.
Monitor Tolerance and Relevant Clinical Factors — Providers should monitor patient tolerance and relevant clinical factors throughout the course of use.
Treatment Decisions Remain With the Licensed Healthcare Professional — All treatment, prescribing, and dosing decisions remain solely the responsibility of the appropriately licensed healthcare professional.
ALML provides product and educational information for healthcare professionals. This information is not a substitute for prescribing information, pharmacy labeling, applicable law, or independent clinical judgment.
Available Options
Option 1
Verified formulations and strengths will be updated based on current pharmacy availability.
Dosing & Reconstitution
For provider use only. Calculates reconstitution math — does not select or recommend a patient dose.
Product Dosing Schedule
Provider Inputs
Calculated Outputs
Concentration
—
Medication amount ÷ diluent mL
Volume to Draw
—
Desired dose ÷ concentration
U-100 Syringe Units
—
Volume to draw × 100 — 100 syringe units = 1.00 mL · 1 syringe unit = 0.01 mL
| Low / Starting Dose | 2 mg once daily |
| Standard Dose | 3.5 mg once daily |
| High Dose | 5 mg once daily |
| Frequency | Daily |
| Dose Unit | mg/day |
| Administrations Per Week | 7 |
Dosing information is provided for healthcare-professional reference only when verified. Patient-specific dosing and prescribing decisions remain the responsibility of the treating healthcare professional.
This tool performs reconstitution/administration math only. It does not select, recommend, or validate a patient dose. Dosing decisions are the responsibility of the prescribing healthcare provider.
Ask ALML
Ask ALML may identify TB-500 / Thymosin Beta-4 as a product for a healthcare professional to explore when the described patient goals involve recovery, tissue repair, musculoskeletal support, or regenerative wellness.
The match is informational. Ask ALML is designed to help healthcare professionals navigate the ALML portfolio and identify potentially relevant options for further clinical consideration. It does not diagnose a patient, prescribe treatment, determine medical necessity, or select patient-specific dosing.
Submit an order request or ask about availability. A request is not a guaranteed order — every inquiry goes to ALML staff for manual review and follow-up.
ALML does not guarantee that any specific therapy can be supplied. Availability is confirmed through manual review of each request.